Literature DB >> 10581367

Structural, mechanistic and clinical aspects of MRP1.

D R Hipfner1, R G Deeley, S P Cole.   

Abstract

The cDNA encoding ATP-binding cassette (ABC) multidrug resistance protein MRP1 was originally cloned from a drug-selected lung cancer cell line resistant to multiple natural product chemotherapeutic agents. MRP1 is the founder of a branch of the ABC superfamily whose members (from species as diverse as plants and yeast to mammals) share several distinguishing structural features that may contribute to functional and mechanistic similarities among this subgroup of transport proteins. In addition to its role in resistance to natural product drugs, MRP1 (and related proteins) functions as a primary active transporter of structurally diverse organic anions, many of which are formed by the biotransformation of various endo- and xenobiotics by Phase II conjugating enzymes, such as the glutathione S-transferases. MRP1 is involved in a number of glutathione-related cellular processes. Glutathione also appears to play a key role in MRP1-mediated drug resistance. This article reviews the discovery of MRP1 and its relationships with other ABC superfamily members, and summarizes current knowledge of the structure, transport functions and relevance of this protein to in vitro and clinical multidrug resistance.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10581367     DOI: 10.1016/s0005-2736(99)00168-6

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  72 in total

1.  Origin of multidrug resistance in cells with and without multidrug resistance genes: chromosome reassortments catalyzed by aneuploidy.

Authors:  P Duesberg; R Stindl; R Hehlmann
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

2.  Requirement of the N-terminal extension for vacuolar trafficking and transport activity of yeast Ycf1p, an ATP-binding cassette transporter.

Authors:  Deborah L Mason; Susan Michaelis
Journal:  Mol Biol Cell       Date:  2002-12       Impact factor: 4.138

3.  Determinant of the extracellular location of the N-terminus of human multidrug-resistance-associated protein.

Authors:  J T Zhang
Journal:  Biochem J       Date:  2000-06-15       Impact factor: 3.857

4.  Saracatinib (AZD0530) is a potent modulator of ABCB1-mediated multidrug resistance in vitro and in vivo.

Authors:  Ke-Jun Liu; Jie-Hua He; Xiao-Dong Su; Hong-May Sim; Jing-Dun Xie; Xing-Gui Chen; Fang Wang; Yong-Ju Liang; Satyakam Singh; Kamlesh Sodani; Tanaji T Talele; Suresh V Ambudkar; Zhe-Sheng Chen; Hai-Ying Wu; Li-Wu Fu
Journal:  Int J Cancer       Date:  2012-06-13       Impact factor: 7.396

Review 5.  Pharmacogenomics and systems biology of membrane transporters.

Authors:  Qing Yan
Journal:  Mol Biotechnol       Date:  2005-01       Impact factor: 2.695

Review 6.  Rafts as missing link between multidrug resistance and sphingolipid metabolism.

Authors:  J W J Hinrichs; K Klappe; J W Kok
Journal:  J Membr Biol       Date:  2005-01       Impact factor: 1.843

Review 7.  Structure-activity relationships of tariquidar analogs as multidrug resistance modulators.

Authors:  Ilza K Pajeva; Michael Wiese
Journal:  AAPS J       Date:  2009-06-06       Impact factor: 4.009

Review 8.  Positron emission tomography diagnostic imaging in multidrug-resistant hepatocellular carcinoma: focus on 2-deoxy-2-(18F)Fluoro-D-Glucose.

Authors:  Ana F Brito; Mónica Mendes; Ana M Abrantes; José G Tralhão; Maria F Botelho
Journal:  Mol Diagn Ther       Date:  2014-10       Impact factor: 4.074

9.  Role of glutathione in the multidrug resistance protein 4 (MRP4/ABCC4)-mediated efflux of cAMP and resistance to purine analogues.

Authors:  Liqi Lai; Theresa M C Tan
Journal:  Biochem J       Date:  2002-02-01       Impact factor: 3.857

Review 10.  The role of half-transporters in multidrug resistance.

Authors:  S E Bates; R Robey; K Miyake; K Rao; D D Ross; T Litman
Journal:  J Bioenerg Biomembr       Date:  2001-12       Impact factor: 2.945

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.